About Axenis
Axenis is a Healthcare company based in Paris (France) founded in 2010, and was acquired by GenOway in September 2018. Chimeric in-vivo mouse models for biomedical research are developed. Its focus areas include Life Sciences, Genomics, Genomics Research and Research Models.
Company details
Axenis was founded in 2010 in Paris, France, within the biotechnology sector. Immunocompromised mice, lacking T-cells, B-cells, and NK cells through Rag2-- and IL-2R-- modifications, are grafted with human blood cells to create the BRGS HIS model. This humanized immune system is applied in studies of immunology, inflammation, infectious diseases, vaccine and drug screening, oncology, stem cell transplantation, gene therapy, and personalized medicine.
- InvestorsEuropean Commission
& 2 more
- Acquired byGenOway
(Sep 2018)
Funding Insights of Axenis
- Total Rounds 2
- First Round $55,006
(Oct 2015)
- Investors Count 2
All 2 funding rounds of Axenis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | Grant | – | – | ||
| Oct 2015 | $55,006 | Grant | – | – |
3 investors in total: 3 institutional.
Investors in Axenis
Axenis has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include European Commission, GenOway and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Institution of the European Union responsible for upholding the EU treaties | 1958 | ec.europa.eu | Brussels, Belgium | |
Provider of transgenic rodent models and customized cell lines for preclinical development | 1999 | genoway.com | Lyon, France |
Investor details for Axenis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Axenis
4 dated milestones of Axenis across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Axenis is founded.
- Funding First funding round of $55K.
- Exit Acquired by GenOway.
- Funding Latest funding round, Grant,.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Axenis
Complete news archive for Axenis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Axenis
Axenis was founded in 2010 and raised its 1st funding round 5 years after it was founded.
Axenis is headquartered in Paris, France.
Axenis was founded in 2010 in Paris, France, within the biotechnology sector. Immunocompromised mice, lacking T-cells, B-cells, and NK cells through Rag2-- and IL-2R-- modifications, are grafted with human blood cells to create the BRGS HIS model. This humanized immune system is applied in studies of immunology, inflammation, infectious diseases, vaccine and drug screening, oncology, stem cell transplantation, gene therapy, and personalized medicine.
Axenis has 3 investors. Key investors include European Commission, GenOway, and EIC Fund.
Yes. Axenis was acquired by GenOway in September 2018.